Why Big Pharma Is Now Racing to Develop Psychedelic-Based Medicines

Psychedelics are drawing major Big Pharma interest because mainstream psychiatric options are failing many patients and psychedelic therapies promise a more durable effect from one or a few guided doses. The article points to recent momentum, including Compass Pathways' Phase 3 psilocybin results for depression and AbbVie's reported acquisition of Gilgamesh Pharmaceuticals' psychedelic candidate bretisilocin. It also frames market growth projections and a rapidly expanding Phase II and Phase 3 pipeline as signals that psychedelics are becoming a serious pharmaceutical category. Regulation and trial design are presented as decisive. The FDA's rejection of MDMA-assisted therapy for PTSD is portrayed as a lesson that strengthens expectations for tighter methodology and more standardized therapeutic protocols. For brain health and dementia care, the piece emphasizes that dementia-specific psychedelic trials are not yet underway, but that serotonin receptor activity and neuroplasticity mechanisms could matter for future research. It also highlights pricing and access risks driven by a patent race: companies may patent modified molecules, formulations, and delivery methods that create exclusivity but could raise costs for patients who need these treatments most.